Solara Active Pharma Sciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Solara Active Pharma Sciences Ltd reported a 1.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 9.6%.
• Its expenses for the quarter were up by 4.7% QoQ and down 4.5% YoY.
• The net profit decreased 196.0% QoQ and decreased 226.1% YoY.
• The earnings per share (EPS) of Solara Active Pharma Sciences Ltd declined at 2.36 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Solara Active Pharma Sciences Ltd is a company operating in the pharmaceutical industry, focusing on the development and production of active pharmaceutical ingredients (APIs). The company is known for its significant presence in the global pharmaceutical market, providing a range of APIs to various pharmaceutical companies. Solara's portfolio includes a wide variety of therapeutic categories, reflecting its robust research and development capabilities. While specific recent developments are not detailed in the provided data, companies in this sector often engage in partnerships, expansions, or product launches to enhance their market position. Solara Active Pharma Sciences Ltd, like many in its industry, must navigate the complexities of regulatory compliance and competitive market dynamics.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Solara Active Pharma Sciences Ltd reported a total income of ₹314.03 crores. This represents a decrease from the previous quarter (Q1FY26), where the total income stood at ₹320.13 crores, marking a quarter-over-quarter (QoQ) decline of 1.9%. Compared to the same quarter in the previous fiscal year (Q2FY25), where the total income was ₹347.27 crores, the year-over-year (YoY) decline is 9.6%. These figures illustrate the company's revenue performance over these periods. The data does not provide information on the specific reasons for these changes in revenue.

Profitability

For Q2FY26, Solara Active Pharma Sciences Ltd recorded a profit before tax (PBT) of -₹10.10 crores, indicating a loss for the period. This is a significant change from the previous quarter (Q1FY26), where the PBT was ₹10.52 crores, reflecting a decrease of 196.0% on a QoQ basis. Compared to Q2FY25, where the PBT was ₹8.01 crores, the YoY change is -226.1%. The profit after tax (PAT) mirrors the PBT, with a reported figure of -₹10.10 crores for Q2FY26, as there were no tax liabilities recorded. Earnings per share (EPS) for Q2FY26 was -₹2.36, a drop from ₹2.46 in Q1FY26 and ₹2.54 in Q2FY25, showing a QoQ decrease of 195.9% and a YoY decrease of 192.9%.

Operating Metrics

The financial data for Solara Active Pharma Sciences Ltd in Q2FY26 shows total expenses of ₹324.13 crores, which is higher than the ₹309.61 crores recorded in Q1FY26, indicating a QoQ increase of 4.7%. When compared to Q2FY25, where total expenses were ₹339.26 crores, there is a YoY decrease of 4.5%. The increase in expenses from the previous quarter contrasts with the revenue and profitability trends, suggesting a complex financial environment during this period. Key financial ratios such as P/E ratio, debt-to-equity ratio, and current ratio are not available in the provided data, hence cannot be calculated. The data does not elaborate on the operational activities that may have contributed to these financial outcomes.